| Income statement (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cost of revenue | 2.33M | 2.46M | 4.39M | 5.14M | 3.31M | |
| Research and development | 5.83M | 11.33M | 18.38M | 16.98M | 6.33M | 4.68M |
| Operating expenses | 9.57M | 14.74M | 25.46M | 28.53M | 12.37M | 5.97M |
| Operating income | -112.00M | -103.00M | ||||
| EBITDA | -111.93M | -102.95M | ||||
| Income before tax | -8.99M | -13.95M | -24.22M | -28.18M | -12.48M | 5.95M |
| Income tax | 0 | 0 | 0 | -534.0K | 0 | 0 |
| Net income | -8.99M | -13.95M | -24.22M | -27.65M | -12.48M | -5.95M |
| EPS | 0.02 | 0.04 | 0.10 | 0.12 | 0.06 | |
| EPS (diluted) | 0.02 | 0.04 | 0.10 | 0.12 | 0.06 | 0.04 |
| Diluted shares | 510.23M | 359.05M | 235.00M | 227.59M | 207.47M |
From Chemomab Therapeutics Ltd. American Depositary Share's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.